GW Pharmaceuticals Announces The Closing Of U.S. Public Offering Of American Depositary Shares (Adss) Totaling Approximately $169.8 Million On The NASDAQ Global Market And Full Exercise Of Underwriters' Option To Purchase Additional Adss
6/26/2014 7:41:40 AM
LONDON, June 25, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced offering on the NASDAQ Global Market by GW and certain of its selling shareholders of 1,700,000 American Depositary Shares (ADSs) and the full exercise by the underwriters of their option to purchase 255,000 additional ADSs from GW at a price of $86.83 per ADS. The ADSs sold in the offering consisted of 1,455,000 ADSs sold by the Company, and 500,000 ADSs sold by the selling shareholders, and raised gross proceeds to GW of $126.3 million (before deducting underwriting discount, commissions and offering expenses). GW did not receive any proceeds from the sale of ADSs by the selling shareholders in this offering.
Help employers find you! Check out all the jobs and post your resume.
comments powered by